Author:
Ingebrigtsen Erlend,Persett Per Sverre,Brekke Mette,Heyerdahl Fridtjof,Hovda Knut Erik,Vallersnes Odd Martin
Abstract
AbstractBackgroundThe use of central stimulant drugs causes significant morbidity. We describe poisonings with central stimulant drugs and compare the different central stimulants concerning combinations with other drugs, treatment, and clinical course. MethodsPatients presenting from 1 October 2013 to 31 March 2016 with poisoning related to the recreational use of central stimulant drugs were retrospectively included at a primary care emergency outpatient clinic and at a hospital emergency department in Oslo, Norway. Diagnosis of toxic agents was mainly based on the clinical assessment of the doctor treating the patient. Amphetamine and methamphetamine were co-categorized as amphetamine.ResultsAmong the 1131 cases of acute poisoning with central stimulant drugs at the outpatient clinic, amphetamine was involved in 808 (71.4%), cocaine in 252 (22.3%) methylenedioxymethamphetamine (MDMA) in 104 (9.2%), and methylphenidate in 13 (1.1%). Among the 211 cases at the hospital, amphetamine was involved in 167 (79.1%), cocaine in 60 (28.4%), and MDMA in 38 (18.0%). Amphetamine was frequently combined with opioids (40.1% at the outpatient clinic and 41.9% at the hospital) and benzodiazepines (28.3% and 45.5%), while MDMA often was combined with ethanol (64.4% and 71.1%), as was cocaine (62.7% and 61.7%). Sedation was given in 5.2% and 38.4% of cases, naloxone in 9.4% and 37.0%, and flumazenil in 0.1% and 28.0%. In total, 16.5% of the cases at the outpatient clinic were transferred to a hospital for medical review and 8.5% to a psychiatric hospital. Among the hospital patients, 92.9% were admitted to intensive care.ConclusionAmphetamine was the most common central stimulant drug involved in acute poisoning in Oslo, often combined with opioids and benzodiazepines.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. United Nations Office on Drugs Crime (UNODC). World drug report 2022. Vienna: United Nations Publications; 2022.
2. Hoots B, Vivolo-Kantor A, Seth P. The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States. Addiction. 2020;115:946–58.
3. Skretting A, Bye EK, Vedøy TF, Lund KE. Rusmidler i Norge 2016 [Substances of abuse in Norway]. Oslo: Folkehelseinstituttet; 2016.
4. European monitoring centre for drugs and drug addiction (EMCDDA). European drug report 2016: trends and developments. Lisbon: EMCDDA; 2016.
5. Krabseth HM, Tuv SS, Strand MC, Karinen RA, Wiik E, Vevelstad MS, et al. Novel psychoactive substances. Tidsskr Nor Legeforen. 2016;136:714–7.